Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-012977

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stephen George Dilly
Officer — See Remarks · Director
Period of report
May 10, 2017
Accepted (ET)
May 12, 2017 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF2May 10, 2017S600$20.15D714,708D
Common Stock, $0.0001 par valueF3holding———51,403IBy GRAT 1
Common Stock, $0.0001 par valueF4holding———14,447IBy GRAT 2
Common Stock, $0.0001 par valueF5holding———51,403IBy Wife's GRAT 1
Common Stock, $0.0001 par valueF6holding———14,447IBy Wife's GRAT 2

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

President and Chief Executive Officer